Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Valeo Pharma Inc. (C:VPH)

Business Focus: Pharmaceuticals

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for VPH within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Apr 15, 2021 07:00 ET
Valeo Pharma Announces Commercial Launch of Redesca™ and Redesca HP™
Shipments have commenced across Canada National sales coverage in full deployment through a dedicated key account managers team Private and public reimbursement activities on target. MONTREAL, April 15, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has commenced commercial shipments across Canada of Redesca™ and Redesca HP™, its low molecular weight heparin ("LMWH") biosimilar.  
Read full article
Apr 14, 2021 07:00 ET
Valeo Pharma Announces $4.0 Million Non-Brokered Private Placement of Non-Convertible Debentures
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
9.70
10.44
15.04
Price to Book - most recent quarter
32.54
4.81
4.54
Price to Cash Flow per share - TTM
--
10.73
18.15
Price to Free Cash Flow per share - TTM
--
26.77
29.93
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 31, 2021364,49889,338
Mar 15, 2021275,160-12,105
Feb 28, 2021287,265-50,040
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Valeo Pharma Inc is a Canada-based specialty pharmaceutical company dedicated to the commercialization of prescription products in Canada. With a focus on neurodegenerative diseases, woman's health, and oncology and supportive care, the Company has a portfolio of products and a platform to manage these products through stages of commercialization.

See business summary

 

Twitter

Search (past week) for $VPH.CA

  • No tweets found